BPA, 'BPA-free' and the bisphenol question, without the noise

Bisphenol A, or BPA, is the industrial chemical used to make polycarbonate plastics and epoxy resin linings, and it is where the endocrine-disruption debate is sharpest. The state of play is genuinely split: European regulators concluded there is effectively no safe level and restricted BPA in food packaging, while US regulators maintain that current exposures are safe. Both sides are looking at overlapping evidence and reaching opposite conclusions. That disagreement, not a settled verdict, is the accurate picture.

What changed in Europe

In 2023 the European Food Safety Authority set a tolerable daily intake for BPA of 0.2 nanograms per kilogram of bodyweight per day [s1]. That number is dramatically lower than the agency's own earlier temporary limit set in 2015, and lower than safe-dose estimates used by agencies elsewhere by several orders of magnitude [s1]. The re-evaluation was built primarily on an immune-system endpoint observed in mice [s1]. A near-total restriction on BPA in food-contact materials in the European Union followed, on the reasoning that no realistic dietary intake stays under so low a threshold [s2].

Why the disagreement is real

The lowered limit is contested by scientists, not just industry. A 2024 analysis in Toxicological Sciences argued that the evidence EFSA evaluated "does not support lowering" the intake, criticising the reliance on a limited subset of studies and on an intermediate immune endpoint in mice "that has not been observed in other species" with "no evidence that it is a precursor event to any downstream pathological outcome" [s1]. Several European regulatory agencies raised similar objections during the consultation, and the paper notes those concerns were not resolved in the final evaluation [s1].

The US Food and Drug Administration has held a different position, judging BPA safe at the levels people are actually exposed to through food. The gap between the two comes down to how much weight to put on low-dose animal findings, how relevant a mouse immune endpoint is to humans, and how to handle studies of varying quality — the recurring fault lines of the whole endocrine-disruptor field.

What is not in dispute is that BPA is biologically active as a weak mimic of estrogen, that it is detectable in most people, and that food is the main route of exposure [s2]. The dispute is entirely about the dose at which that activity becomes a health problem, and whether typical human exposures reach it.

The size of the disagreement is easy to understand by the numbers. The 2015 European temporary limit and the 2023 limit differ by orders of magnitude for the same chemical, evaluated by the same agency [s1]. A gap that large is not a refinement; it reflects a fundamental shift in which studies were treated as decisive. When a single regulator can move its own safe-dose estimate by that much in eight years, and other regulators decline to follow, the honest signal to a reader is that the underlying science is unsettled, not that a danger was newly proven or newly dismissed.

The 'BPA-free' trap

The consumer response to the BPA scare was "BPA-free" labelling, and it created a second problem. Manufacturers replaced BPA with close chemical relatives — bisphenol S and bisphenol F among them — that are "also toxic but less regulated and insufficiently studied," in the words of a 2026 systematic review [s2]. The substitutes share the structural features that make BPA an endocrine mimic, so swapping one bisphenol for another does not necessarily remove the property of concern; it removes the name on the label.

This is the "regrettable substitution" pattern, and here it has a measurable consequence. The same review found that combined dietary intake of BPA and its analogues can produce a hazard index above 1 — a screening signal that cumulative exposure exceeds the reference level — driven largely by BPA's sharply reduced tolerable intake [s2]. A hazard index over 1 is a flag for closer assessment, not a diagnosis, but it means "BPA-free" cannot be read as "bisphenol-free" or as "safe."

What is established, and what is not

Established: BPA is a weak hormone mimic, exposure is near-universal through food, Europe has judged the safe intake to be extremely low and restricted the chemical, and the common substitutes are structurally similar and less studied [s1][s2]. Also established: credentialed scientists dispute the European limit, and the FDA has not matched it [s1].

Not established: that BPA at ordinary dietary exposure causes disease in humans, which is the claim the whole argument turns on and the one the evidence does not yet close. The animal endpoints are real; their human relevance is what the two regulatory camps cannot agree on [s1].

For a reader, the useful distinctions are these. The European restriction reflects a precautionary reading of contested evidence, not a demonstrated body count. "BPA-free" tells you which bisphenol is absent, not whether a substitute with similar activity is present [s2]. And the honest state of the science is disagreement among serious people about dose — which is less satisfying than either "proven danger" or "totally safe," and closer to true than both.

This article is informational and is not medical advice.

Sources

• Evidence evaluated by European Food Safety Authority does not support lowering the temporary tolerable daily intake for bisphenol A — Toxicological Sciences, 2024-03-01
• Simultaneous Determination of Bisphenol A and Its Analogues in Food Matrixes: Cumulative Exposure Assessment Following New Regulatory Restrictions—A Systematic Review — Foods, 2026-03-21